In addition, we found that predicted survival outcomes from the combined therapy with three drugs were greatly improved (Figure 9), consistent with the results from clinic indicating that the use of BTZ, LEN and Thal dramatically changed outcomes for patients with relapsed myeloma [41]. Here, CASC3 is linked to plasma cell myeloma.